{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:01:06Z","timestamp":1774958466315,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Independent Research Grant","award":["2005-0039"],"award-info":[{"award-number":["2005-0039"]}]}],"content-domain":{"domain":["psy-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.psychres.2014.05.039","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T02:52:49Z","timestamp":1401677569000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine"],"prefix":"10.1016","volume":"219","author":[{"given":"Piotr","family":"Tybura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Trze\u015bniowska-Druka\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Bienkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Beszlej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Frydecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Samochowiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Grzywacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Samochowiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.psychres.2014.05.039_bib1","first-page":"985","article-title":"Physicians\u2019 opinion on the use of perazine in the treatment of mental disorders\u2014results of the Delphi consensus study","volume":"46","author":"Adamowski","year":"2012","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","article-title":"A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia","volume":"6","author":"Arinami","year":"1997","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib4","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/schbul\/sbn114","article-title":"Pharmacogenetics in psychiatry: are we ready for widespread clinical use?","volume":"6","author":"Arranz","year":"2008","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1016\/j.psychres.2014.05.039_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4002142","article-title":"Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions","volume":"13","author":"Bakker","year":"2008","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.mp.4000987","article-title":"Association between the ionotropic glutamate receptor kainite 3(GRIK 3) ser310ala polymorphism and schizophrenia","volume":"7","author":"Begni","year":"2002","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib7","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1073\/pnas.88.4.1416","article-title":"Human catechol-o-methyltransferase: cloning and expression of membrane-associated form","volume":"88","author":"Bertocci","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.psychres.2014.05.039_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hup.2288","article-title":"Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain","volume":"28","author":"Brandl","year":"2013","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archpsyc.55.1.67","article-title":"The genetic epidemiology of schizophrenia in a Finnish twin cohort: a population-based modeling study","volume":"55","author":"Cannon","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.0.CO;2-U","article-title":"Twin studies of schizophrenia","volume":"97","author":"Cardno","year":"2000","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0888-7543(05)80286-1","article-title":"Organization of the human monoamine oxidase genes and long-range physical mapping around them","volume":"14","author":"Chen","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.psychres.2014.05.039_bib12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/1096-8628(20001204)96:6<712::AID-AJMG2>3.0.CO;2-U","article-title":"Tardive dyskinesia is not associated with the serotonin gene polymorphism. (5-HTTLPR) in Chinese","volume":"96","author":"Chong","year":"2000","journal-title":"American Journal of Medical Genetics"},{"issue":"5","key":"10.1016\/j.psychres.2014.05.039_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145707007547","article-title":"Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis","volume":"10","author":"De Luca","year":"2007","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2014.05.039_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","article-title":"The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine\u2019s actions?","volume":"178","author":"Davies","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.05.039_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00041444-200509000-00002","article-title":"Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India","volume":"15","author":"Deshpande","year":"2005","journal-title":"Psychiatric Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1192\/bjp.177.6.511","article-title":"Causes and consequences of duration of untreated psychosis in schizophrenia","volume":"177","author":"Drake","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib17","first-page":"57","article-title":"Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia","volume":"40","author":"Ellingrod","year":"2007","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.psychres.2014.05.039_bib18","series-title":"Clinical Trials in Psychiatry","author":"Everitt","year":"2008"},{"key":"10.1016\/j.psychres.2014.05.039_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00008571-199708000-00002","article-title":"Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism","volume":"7","author":"Finckh","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004850-200507000-00002","article-title":"Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study","volume":"20","author":"Gasquet","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.05.039_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/331442a0","article-title":"Characterization of the common genetic defect in humans deficient in debrisoquine metabolism","volume":"331","author":"Gonzalez","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.psychres.2014.05.039_bib22","series-title":"Schizophrenia Genesis: The Origins of Madness","author":"Gottesman","year":"1991"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1096-8628(19990205)88:1<83::AID-AJMG15>3.0.CO;2-0","article-title":"Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets","volume":"88","author":"Greenberg","year":"1999","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/0888-7543(92)90316-K","article-title":"Chromosomal mapping of human catecholamine-o-methyltransferase gene to 22q11.1\u2013q11.2","volume":"12","author":"Grossman","year":"1992","journal-title":"Genomics"},{"issue":"10","key":"10.1016\/j.psychres.2014.05.039_bib25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/BF01273314","article-title":"The human serotonin transporter gene polymorphism\u2014basic research and clinical implications","volume":"104","author":"Heils","year":"1997","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.psychres.2014.05.039_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-9338(03)00005-1","article-title":"Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene","volume":"18","author":"Herken","year":"2003","journal-title":"European Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.05.039_bib27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF01233097","article-title":"The serotonin receptor subtype 2 locus HTR2 is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14","volume":"16","author":"Hsieh","year":"1990","journal-title":"Somatic Cell and Molecular Genetics"},{"issue":"8","key":"10.1016\/j.psychres.2014.05.039_bib28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4088\/JCP.11m06916","article-title":"Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia","volume":"73","author":"Houston","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2014.05.039_bib29","first-page":"274","article-title":"Epidemiology of schizophrenia: the global burden of disease and disability","volume":"250","author":"Jablensky","year":"2000","journal-title":"European Archives of Psychiatry and Neurological Sciences"},{"key":"10.1016\/j.psychres.2014.05.039_bib30","first-page":"1171","article-title":"Pharmacological standards In schizophrenia treatment (Polish)","volume":"40","author":"Jarema","year":"2006","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib31","first-page":"90","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"3","author":"J\u00f6nsson","year":"1999","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.psychres.2014.05.039_bib33","first-page":"453","article-title":"HIV-associated neurocognitive disorders","volume":"47","author":"Kalinowska","year":"2013","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib34","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/ajp.2006.163.8.1316","article-title":"Tardive dyskinesia circa 2006","volume":"163","author":"Kane","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000293173","article-title":"Towards more effective antipsychotic treatment","volume":"25","author":"Kane","year":"1994","journal-title":"British Journal of Psychiatry \u2013 Supplement"},{"key":"10.1016\/j.psychres.2014.05.039_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2014.05.039_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1096-8628(19970221)74:1<104::AID-AJMG21>3.0.CO;2-U","article-title":"Can we find genes for schizophrenia?","volume":"74","author":"Kidd","year":"1997","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd1801","article-title":"Pharmacogenetics-based therapeutic recommendations \u2013 ready for clinical practice?","volume":"4","author":"Kirchheiner","year":"2005","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.psychres.2014.05.039_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijlp.2005.08.007","article-title":"Economic issues in access to medications: schizophrenia treatment in England","volume":"28","author":"Knapp","year":"2005","journal-title":"International Journal of Law and Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-o-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.psychres.2014.05.039_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","article-title":"DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia","volume":"20","author":"Lencz","year":"2010","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.psychres.2014.05.039_bib43","series-title":"Perazine for schizophrenia (Review). The Cochrane Collaboration","author":"Leucht","year":"2014"},{"key":"10.1016\/j.psychres.2014.05.039_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2014.05.039_bib45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.bp.107.037218","article-title":"CATIE and CUtLASS: can we handle the truth?","volume":"192","author":"Lewis","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.63.10.1069","article-title":"Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)","volume":"63","author":"Lieberman","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib47","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.psychres.2014.05.039_bib48","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane bound catechol-o-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.psychres.2014.05.039_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4838(95)00071-2","article-title":"Cloning, expression and structure of catechol-o-methyltransferase","volume":"1251","author":"Lundstrom","year":"1995","journal-title":"Biochimica et Biophysica Acta"},{"issue":"2","key":"10.1016\/j.psychres.2014.05.039_bib50","first-page":"213","article-title":"The efficacy of cognitive neurorehabilitation with RehaCom program in schizophrenia patients","volume":"47","author":"Mak","year":"2013","journal-title":"Psychiatria Polska"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib51","first-page":"77","article-title":"The efficacy of cognitive rehabilitation with RehaCom programme in schizophrenia patients. The role of selected genetic polymorphisms in successful cognitive rehabilitation","volume":"20","author":"Mak","year":"2013","journal-title":"Annals of Agricultural and Environmental Medicine"},{"key":"10.1016\/j.psychres.2014.05.039_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002018-199309060-00005","article-title":"Adverse effects of antipsychotic drugs","volume":"9","author":"Malhotra","year":"1993","journal-title":"Drug Safety"},{"key":"10.1016\/j.psychres.2014.05.039_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1176\/appi.ajp.161.5.780","article-title":"Pharmacogenetics of psychotropic drug response","volume":"161","author":"Malhotra","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib54","series-title":"Seminars in Psychiatric Genetics","first-page":"87","author":"McGuffin","year":"1994"},{"key":"10.1016\/j.psychres.2014.05.039_bib55","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1471-4159.2001.00647.x","article-title":"The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons","volume":"79","author":"Michelhaugh","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.psychres.2014.05.039_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.psychres.2014.05.039_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib58","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2014.05.039_bib59","first-page":"315","article-title":"Molecular characterization of the human EAA5 (GluR7) receptor: high-affinity kainite receptor with novel potential RNA editing sites","volume":"2","author":"Nutt","year":"1994","journal-title":"Receptors and Channels"},{"issue":"5","key":"10.1016\/j.psychres.2014.05.039_bib60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1734-1140(13)71476-2","article-title":"BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample","volume":"65","author":"Pe\u0142ka-Wysiecka","year":"2013","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.psychres.2014.05.039_bib61","first-page":"329","article-title":"Personalized antipsychotic treatment. The adverse effects perspectives","volume":"2","author":"Plesni\u010dar","year":"2010","journal-title":"Psychiatria Danubina"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone","volume":"33","author":"Potkin","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.05.039_bib63","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1073\/pnas.90.6.2542","article-title":"Antidepressant \u2013 and cocaine \u2013 sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization","volume":"90","author":"Ramamoorthy","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.psychres.2014.05.039_bib64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-9964(98)00153-4","article-title":"Application of pharmacogenetics to psychotic disorders: the first consensus conference","volume":"37","author":"Rietschel","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2014.05.039_bib65","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.1988.01800360017003","article-title":"The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures","volume":"45","author":"Robins","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2014.05.039_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2014.05.039_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s004390050816","article-title":"A functional polymorphism in the monoamine oxidase A gene promoter","volume":"103","author":"Sabol","year":"1998","journal-title":"Human Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib68","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00008571-200007000-00010","article-title":"Predominant influence of the 3\u2032-region of dopamine D2 receptor gene (DRD2) on the clinical phenotype in German alcoholics","volume":"10","author":"Samochowiec","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib69","series-title":"Psychopharmacology. The Fourth Generation of Progress","first-page":"431","article-title":"Serotonin receptors: signal transduction pathways","author":"Sanders-Busch","year":"1995"},{"key":"10.1016\/j.psychres.2014.05.039_bib70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00217369","article-title":"A 40-nucleotide repeat polymorphism in the human dopamine transporter gene","volume":"91","author":"Sano","year":"1993","journal-title":"Human Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib71","doi-asserted-by":"crossref","first-page":"9025","DOI":"10.1523\/JNEUROSCI.20-24-09025.2000","article-title":"Unequal expression of allelic kainate receptor GluR7 mRNAs in human brains","volume":"20","author":"Schiffer","year":"2000","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.psychres.2014.05.039_bib72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.mp.4000842","article-title":"Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia","volume":"6","author":"Segman","year":"2001","journal-title":"Molecular Psychiatry"},{"issue":"152","key":"10.1016\/j.psychres.2014.05.039_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s002130000521","article-title":"Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility","volume":"2000","author":"Segman","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2014.05.039_bib74","series-title":"Antipsychotics and Mood Stabilizers: Stahl\u2019s Essential Psychopharmacology","author":"Stahl","year":"2008"},{"key":"10.1016\/j.psychres.2014.05.039_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/j.psychres.2014.05.039_bib76","first-page":"349","article-title":"ANKK1 gene in psychiatry","volume":"45","author":"Suchanecka","year":"2011","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-3223(01)01076-9","article-title":"Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor","volume":"50","author":"Tan","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"16","key":"10.1016\/j.psychres.2014.05.039_bib78","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/mds.22707","article-title":"Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis","volume":"24","author":"Tenback","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1016\/j.psychres.2014.05.039_bib79","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00041444-200512000-00011","article-title":"Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs","volume":"15","author":"Theisen","year":"2005","journal-title":"Psychiatric Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1600-0447.1991.tb03178.x","article-title":"Interaction between genetic vulnerability and family environment: the Finnish adoptive family study of schizophrenia","volume":"84","author":"Tienari","year":"1991","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1016\/j.psychres.2014.05.039_bib82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0022-3956(87)90091-4","article-title":"The Finnish adoptive family study of schizophrenia","volume":"21","author":"Tienari","year":"1987","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.psychres.2014.05.039_bib83","first-page":"1171","article-title":"Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency","volume":"6","author":"Tybura","year":"2011","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/2211557911201010047","article-title":"Pharmacogenetics of antipsychotic drugs in schizophrenia treatment","volume":"1","author":"Tybura","year":"2012","journal-title":"Current Psychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2014.05.039_bib85","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1734-1140(12)70848-4","article-title":"Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients","volume":"64","author":"Tybura","year":"2012","journal-title":"Pharmacological Reports"},{"issue":"2","key":"10.1016\/j.psychres.2014.05.039_bib86","first-page":"197","article-title":"Functional polymorphism of genes inactivating biogenic amines and cognitive deficits in paranoid schizophrenia","volume":"47","author":"Tylec","year":"2013","journal-title":"Psychiatria Polska"},{"key":"10.1016\/j.psychres.2014.05.039_bib87","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0888-7543(05)80138-7","article-title":"Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR","volume":"14","author":"Vandenbergh","year":"1992","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.psychres.2014.05.039_bib88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/hmg\/2.3.338","article-title":"An MspI polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis","volume":"2","author":"Warren","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.psychres.2014.05.039_bib89","series-title":"Pharmacogenetics","author":"Weber","year":"1997"},{"key":"10.1016\/j.psychres.2014.05.039_bib90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.psychres.2004.02.018","article-title":"Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation","volume":"133","author":"Wehmeier","year":"2005","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2014.05.039_bib91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2014.05.039_bib92","first-page":"41","article-title":"Concordance between diagnoses based on the Composite International Diagnostic Interview (CIDI) and clinical diagnoses made by psychiatrists","volume":"22","author":"Welbel","year":"2013","journal-title":"Advances in Psychiatry and Neurology"},{"key":"10.1016\/j.psychres.2014.05.039_bib93","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2014.05.039_bib94","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.mp.4002023","article-title":"Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients","volume":"12","author":"Zai","year":"2007","journal-title":"Molecular Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178114004363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178114004363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T01:27:14Z","timestamp":1565486834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178114004363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0165178114004363"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2014.05.039","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2014.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}